https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-28 / Clin. Cancer Res. 2014 May;20(9):2433-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-28 / Clin. Cancer Res. 2014 May;20(9):2433-442014-02-28 00:00:002019-02-15 08:39:40Phase I dendritic cell p53 peptide vaccine for head and neck cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-27 / Oncoimmunology 2014 Jan;3(1):e27589
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-27 / Oncoimmunology 2014 Jan;3(1):e275892014-02-27 00:00:002019-02-15 08:48:45Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-22 / Strahlenther Onkol 2014 Sep;190(9):815-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-22 / Strahlenther Onkol 2014 Sep;190(9):815-222014-02-22 00:00:002019-02-15 09:17:11DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-18 / J Immunother Cancer 2014;2:4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-18 / J Immunother Cancer 2014;2:42014-02-18 00:00:002019-02-15 08:46:24Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-05 / Cancer Immunol Res 2014 May;2(5):404-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-05 / Cancer Immunol Res 2014 May;2(5):404-92014-02-05 00:00:002019-02-15 08:48:45Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):53-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):53-632014-02-01 00:00:002019-02-15 08:35:18Immunotherapy in lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Anticancer Res. 2014 Feb;34(2):565-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Anticancer Res. 2014 Feb;34(2):565-742014-02-01 00:00:002014-02-01 00:00:00Fighting fire with fire: the revival of thermotherapy for gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-452014-02-01 00:00:002014-02-01 00:00:00Immunotherapy prospects in the treatment of lung cancer and mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-13 / Hum Vaccin Immunother 2014;10(4):970-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-13 / Hum Vaccin Immunother 2014;10(4):970-62014-01-13 00:00:002014-01-13 00:00:00Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-06 / Oncoimmunology 2014 Jan;3(1):e27622
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-06 / Oncoimmunology 2014 Jan;3(1):e276222014-01-06 00:00:002019-02-15 09:21:25Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
